Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice

Infection and Immunity

Volumn 78, Issue 10, 2010, Pages 4356-4362

  Musson, Julie A ^a   Ingram, Rebecca ^b   Durand, Guillaume ^d   Ascough, Stephanie ^b   Waters, Emma L ^c   Hartley, M Gillian ^c   Robson, Timothy ^a   Maillere, Bernard ^d   Williamson, E Diane ^c   Sriskandan, Shiranee ^b   Altmann, Daniel ^b   Robinson, John H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^d CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CAF1 ANTIGEN; HLA DR1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HLA SYSTEM; HYBRIDOMA; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; T LYMPHOCYTE; TRANSGENIC MOUSE; YERSINIA PESTIS;

ANIMALS; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HLA ANTIGENS; HLA-DR1 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; PROTEIN BINDING; YERSINIA PESTIS;

EID: 77957744887     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00195-10     Document Type: Article

References (51)

1. Altmann, D. M., D. C. Douek, A. J. Frater, C. M. Hetherington, H. Inoko, and J. I. Elliott. 1995. The T-cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J. Exp. Med. 181:867-875.
2. Anderson, G. W., P. L. Worsham, C. R. Bolt, G. P. Andrews, S. L. Welkos, A. M. Friedlander, and J. P. Burans. 1997. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am. J. Trop. Med. Hyg. 56:471-473.
3. Chichester, J. A., K. Musiychuk, C. E. Farrance, V. Mett, J. Lyons, V. Mett, and V. Yusibov. 2009. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 27:3471-3474.
4. Cornelis, G. R. 2000. Molecular and cell biology aspects of plague. Proc. Natl. Acad. Sci. U. S. A. 97:8778-8783.
5. Cornelis, G. R. 2002. The Yersinia Ysc-Yop type III weaponry. Nat. Rev. Mol. Cell. Biol. 3:742-752.
6. Davis, K. J., D. L. Fritz, M. L. Pitt, S. L. Welkos, P. L. Worsham, and A. M. Friedlander. 1996. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative yersinia-pestis in African green monkeys (Cercopithecus aethiops). Arch. Pathol. Lab. Med. 120:156-163.
7. De Leo, F. R., and B. J. Hinnebusch. 2005. A plague upon the phagocytes. Nat. Med. 11:927-928.
8. Delvig, A. A., and J. H. Robinson. 1998. Two T-cell epitopes from the M5 protein of viable Streptococcus pyogenes engage different pathways of bacterial antigen processing in mouse macrophages. J. Immunol. 160:5267-5272.
9. Do, Y., C. G. Park, Y. S. Kang, S. H. Park, R. M. Lynch, H. Lee, B. S. Powell, and R. M. Steinman. 2008. Broad T-cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur. J. Immunol. 38:20-29.
10. Doytchinova, I. A., and D. R. Flower. 2005. In silico identification of supertypes for class II MHCs. J. Immunol. 174:7085-7095.
11. Drozdov, I. G., et al. 1995. Virulent non-capsulate Yersinia pestis variants constructed by insertion mutagenesis. J. Med. Microbiol. 42:264-268.
12. Du, Y., R. Rosqvist, and A. Forsberg. 2002. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun. 70:1453-1460.
13. Elvin, S. J., and E. D. Williamson. 2004. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb. Pathog. 37:177-184.
14. Eyles, J. E., G. Sharp, E. D. Williamson, I. D. Spiers, and H. O. Alpar. 1998. Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16:698-707.
15. Eyles, J. E., I. D. Spiers, E. D. Williamson, and H. O. Alpar. 1998. Analysis of local and systemic immunological responses after intra-tracheal, intranasal, and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine 16:2000-2009.
16. Fischer, H. G., B. Opel, K. Reske, and A. B. Reske-Kunz. 1988. Granulocyte-macrophage colony-stimulating factor-cultured bone marrow-derived macrophages reveal accessory cell function and synthesis of MHC class II determinants in the absence of external stimuli. Eur. J. Immunol. 18:1151-1158.
17. Galyov, E. E., O. Y. Smirnov, A. V. Karlishev, K. I. Volkovoy, A. J. Denesyuk, I. V. Nazimov, K. S. Rubtsov, V. M. Abramov, S. M. Dalvadyanz, and V. P. Zavyalov. 1990. Nucleotide-sequence of the yersinia-pestis gene encoding f1 antigen and the primary structure of the protein: putative T-cell and B-cell epitopes. FEBS Lett. 277:230-232.
18. Gerke, C., S. Falkow, and Y. H. Chien. 2005. The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T-cell activation. J. Exp. Med. 201:361-371.
19. Hill, J., C. Copse, S. Leary, A. J. Stagg, E. D. Williamson, and R. W. Titball. 2003. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect. Immun. 71:2234-2238.
20. Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, M. Layton, J. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, M. Schoch-Spana, and K. Tonat. 2009. Plague as a biological weapon: medical and public health management. JAMA 283:2281-2290.
21. Ivanov, M. I., B. L. Noel, R. Rampersaud, P. Mena, J. L. Benach, and J. B. Bliska. 2008. Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1-negative Yersinia pestis. Infect. Immun. 76:5181-5190.
22. Jardetzky, T. S., J. C. Gorga, R. Busch, J. B. Rothbard, J. L. Strominger, and D. C. Wiley. 1990. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797-1803.
23. Khan, A. A., J. P. Babu, G. Gupta, and D. N. Rao. 2008. Identifying B- and T-cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis. Vaccine 26: 316-332.
24. Kingston, R., F. Burke, J. H. Robinson, P. A. Bedford, S. M. Jones, S. C. Knight, and E. D. Williamson. 2007. The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T-cell responses. Clin. Exp. Immunol. 149:561-569.
25. Leary, S., K. F. Griffin, E. E. Galyov, J. Hewer, E. D. Williamson, A. Holmstrom, A. Forsberg, and R. W. Titball. 1999. Yersinia outer proteins (YOPs) E, K, and N are antigenic but non-protective compared to V antigen in a murine model of bubonic plague. Microb. Pathog. 26:159-169.
26. Li, B., and R. Yang. 2008. Interaction between Yersinia pestis and the host immune system. Infect. Immun. 76:1804-1811.
27. Marketon, M. M., R. W. De Paolo, K. L. DeBord, B. Jabri, and O. Schneewind. 2005. Plague bacteria target immune cells during infection. Science 309:1739-1741.
28. Matsumoto, H., and G. M. Young. 2009. Translocated effectors of Yersinia. Curr. Opin. Microbiol. 12:94-100.
29. Miller, J., E. D. Williamson, J. H. Lakey, M. J. Pearce, S. M. Jones, and R. W. Titball. 1998. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol. Med. Microbiol. 21:213-221.
30. Moudgil, K. D., and E. E. Sercarz. 2005. Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol. 26:355-359.
31. Musson, J. A., M. Morton, N. Walker, H. M. Harper, H. V. McNeill, E. D. Williamson, and J. H. Robinson. 2006. Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for MHC class II-restricted presentation to T lymphocytes. J. Biol. Chem. 281:26129-26135.
32. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T-cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
33. Parent, M. A., K. N. Berggren, I. K. Mullarky, F. M. Szaba, L. W. Kummer, J. J. Adamovicz, and S. T. Smiley. 2005. Yersinia pestis V protein epitopes recognized by CD4 T cells. Infect. Immun. 73:2197-2204.
34. Prentice, M. B., and L. Rahalison. 2007. Plague. Lancet 369:1196-1207.
35. Reddin, K. M., T. J. Easterbrook, S. M. Eley, P. Russell, V. A. Mobsby, D. H. Jones, G. H. Farrar, E. D. Williamson, and A. Robinson. 1998. Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis. Vaccine 16:761-767.
36. Shim, H.-K., J. A. Musson, H. Harper, H. McNeill, N. Walker, H. Flick-Smith, A. A. von Delwig, E. D. Williamson, and J. H. Robinson. 2006. Mechanisms of MHC class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology 119:385-392.
37. Smiley, S. T. 2008. Immune defense against pneumonic plague. Immunol. Rev. 225:256-271.
38. Texier, C., S. Pouvelle, M. Busson, M. Hervé, D. Charron, A. Ménez, and B. Maillère. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164:3177-3184.
39. Titball, R. W., and E. D. Williamson. 2003. Second and third generation plague vaccines. Adv. Exp. Med. Biol. 529:397-406.
40. Velan, B., E. Bar-Haim, A. Zauberman, E. Mamroud, A. Shafferman, and S. Cohen. 2006. Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration. Infect. Immun. 74:6365-6376.
41. Vita, R., L. Zarebski, J. A. Greenbaum, H. Emami, I. Hoof, N. Salimi, R. Damle, A. Sette, and B. Peters. 2010. The Immune Epitope Database 2.0. Nucleic Acids Res. 38:D854-D862.
42. Vogel, T. U., H. Horton, D. H. Fuller, D. K. Carter, K. Vielhuber, D. H. O'Connor, T. Shipley, J. Fuller, G. Sutter, V. Erfle, N. Wilson, L. J. Picker, and D. I. Watkins. 2002. Differences between T-cell epitopes recognized after immunization and after infection. J. Immunol. 169:4511-4521.
43. Wang, S., S. Joshi, I. Mboudjeka, F. Liu, T. Ling, J. D. Goguen, and S. Lu. 2008. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in BALB/c mice. Vaccine 26:1664-1674.
44. Welkos, S., A. Friedlander, D. McDowell, J. Weeks, and S. Tobery. 1998. V antigen of Yersinia pestis inhibits neutrophil chemotaxis. Microb. Pathog. 24:185-196.
45. Welkos, S. L., K. M. Davis, L. M. Pitt, P. L. Worsham, and A. M. Freidlander. 1995. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib. Microbiol. Immunol. 13:299-305.
46. Williamson, E. D. 2009. Plague. Vaccine 27:D56-D60.
47. Williamson, E. D., S. M. Eley, A. J. Stagg, M. Green, P. Russell, and R. W. Titball. 1997. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15:1079-1084.
48. Williamson, E. D., H. C. Flick-Smith, E. L. Waters, J. Miller, I. Hodgson, C. S. Le Butt, and J. Hill. 2007. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb. Pathog. 42:11-21.
49. Williamson, E. D., and R. W. Titball. 2002. Vaccines against dangerous pathogens. Br. Med. Bull. 62:163-173.
50. Yamanaka, H., T. Hoyt, R. Bowen, X. Yang, K. Crist, S. Golden, M. Maddaloni, and D. W. Pascual. 2009. An IL-12 DNA vaccine coexpressing Yersinia pestis antigens protects against pneumonic plague. Vaccine 27:80-87.
51. Zav'yalov, V., A. V. Zavialov, G. Zav'yalova, and T. Korpela. 2010. Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: structure and function from a clinical standpoint. FEMS Microb. Rev. 34:1-62.